Vir Biotechnology, Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. The filing is an annual report, not a standalone Q4 filing; selected Q4 results are included below. Vir is a clinical-stage immunology company with no approved products or product-sales revenue, developing infectious-disease candidates using antibody, T-cell, innate-immunity and siRNA platforms.
Financial results and liquidity
| Metric | FY2019 | FY2018 |
|---|---|---|
| Total revenue | $8.1 million | $10.7 million |
| Research and development expense | $148.5 million | $100.2 million |
| General and administrative expense | $37.6 million | $29.1 million |
| Operating loss | $178.0 million | $118.7 million |
| Net loss | $174.7 million | $115.9 million |
| Net loss per share, basic and diluted | $5.76 | $15.12 |
| Cash, cash equivalents and investments at year-end | $407.7 million | $98.4 million |
| Working capital at year-end | $343.8 million | $77.9 million |
| Total liabilities at year-end | $88.1 million | $61.6 million |
Amounts are in U.S. dollars. Revenue comprised grants and contract research services, not product sales. Operating cash use was $129.6 million in 2019, versus $94.1 million in 2018; investing cash use was $256.2 million, primarily reflecting purchases of investments, while financing provided $449.2 million. Vir reported no debt outstanding at December 31, 2019. As a development-stage company, it reported losses rather than meaningful operating profitability or margins.
Fourth-quarter 2019 revenue was $1.0 million, operating expenses were $64.7 million, and net loss was $63.8 million. Reported Q4 loss per share was $0.69 basic and $0.71 diluted.
Material changes versus the prior year
- Net loss increased by $58.8 million as operating expenses rose $56.7 million, led by higher R&D spending, headcount, clinical activity and manufacturing costs.
- Revenue declined $2.6 million, primarily because a Gates Foundation grant expired and HIV/TB grant activity timing changed.
- Cash, cash equivalents and investments increased substantially, following a $317.3 million net Series B preferred-stock financing and $126.4 million net proceeds from the October 2019 IPO. Preferred shares converted into common stock upon the IPO.
- Vir’s R&D program advanced: VIR-2218 completed enrollment in Phase 1/2, and VIR-2482 began Phase 1/2 dosing.
Outlook, developments and risks
- Liquidity outlook: Management said year-end cash, cash equivalents and investments were expected to fund the current operating plan for at least 12 months from issuance of the financial statements. The company also expects substantial additional capital will be needed; no quantified financial forecast or product-revenue guidance was provided.
- Pipeline: VIR-2218 (HBV siRNA) showed dose-dependent HBsAg reductions. In the 200 mg cohorts, the average decline at Week 16 was 1.5 log10 after two doses; the company described the candidate as generally well tolerated. These early results do not establish a functional cure. A Phase 2 combination study with pegylated interferon was planned for the second half of 2020.
- COVID-19 impact and programs: The filing describes early SARS-CoV-2 antibody work and a new Alnylam siRNA collaboration. Management anticipated clinical-start delays for VIR-3434 and VIR-1111, and shifted the planned VIR-2482 Phase 2 trial to the Northern Hemisphere flu season. The company cautioned that pandemic-related restrictions could disrupt trials, supply chains and operations.
- Subsequent milestone and collaboration obligations: In March 2020, Vir achieved a VIR-2218 development milestone, triggering a $15.0 million payment and issuance of 1,111,111 common shares to Alnylam. Collaboration and license agreements also carry potentially substantial future milestone, royalty and other payment obligations.
- Key risks: All candidates remain investigational; clinical, regulatory and commercial success is uncertain. Vir depends on third-party manufacturers and research organizations, faces competition and potential financing needs, and has no commercial infrastructure or product revenue. COVID-19 could further delay development and impair operations.
- Unusual accounting item: The company recorded a $13.6 million initial fair-value charge for an Alnylam-related derivative liability after the IPO made the milestone-share feature subject to derivative accounting; the liability was $12.4 million at year-end.
Investor facts to verify
- Review full financial statements and cash-flow disclosures, including restricted cash, investment maturities and the company’s projected cash runway.
- Track subsequent VIR-2218 data, safety follow-up and the design, timing and outcomes of planned combination trials.
- Check actual clinical timelines and trial effects from COVID-19, particularly for VIR-3434, VIR-1111 and VIR-2482.
- Assess future financing needs, potential dilution, and milestone, royalty and profit-sharing obligations under collaboration and acquisition agreements.
- Verify the status of manufacturing scale-up, third-party supply capacity and regulatory plans as programs progress.